Bionomics Limited (BNOX)

NASDAQ: BNOX · IEX Real-Time Price · USD
6.00
0.00 (0.00%)
At close: Sep 27, 2022 12:00 AM
6.42
+0.42 (7.00%)
After-hours: Sep 28, 2022 4:00 PM EDT
0.00%
Market Cap 41.10M
Revenue (ttm) 183,079
Net Income (ttm) -15.11M
Shares Out 6.85M
EPS (ttm) -2.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 38
Open 5.40
Previous Close 6.00
Day's Range 5.30 - 6.00
52-Week Range 5.30 - 22.00
Beta 2.63
Analysts Buy
Price Target 139.20 (+2,220.0%)
Earnings Date n/a

About BNOX

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem ... [Read more...]

Industry Biotechnology
IPO Date Dec 16, 2021
Country Australia
Stock Exchange NASDAQ
Ticker Symbol BNOX
Full Company Profile

Financial Performance

Financial numbers in AUD Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for BNOX stock is "Buy." The 12-month stock price forecast is 139.2, which is an increase of 2,220.00% from the latest price.

Price Target
$139.2
(2,220.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Bionomics to Host KOL Webinar on BNC210 and Social Anxiety Disorder

BNC210 is a First-in-Class Candidate in Clinical Development for the Acute Treatment of Social Anxiety Disorder with FDA Fast Track Designation BNC210 is a First-in-Class Candidate in Clinical Developme...

1 week ago - GlobeNewsWire

Can Bionomics Limited Unsponsored ADR (BNOX) Climb 329% to Reach the Level Wall Street Analysts Expect?

The mean of analysts' price targets for Bionomics Limited Unsponsored ADR (BNOX) points to a 329.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong...

1 week ago - Zacks Investment Research

Bionomics to Participate in Upcoming September Investor Conferences

ADELAIDE, Australia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion channe...

4 weeks ago - GlobeNewsWire

Does Bionomics Limited Unsponsored ADR (BNOX) Have the Potential to Rally 329% as Wall Street Analysts Expect?

The consensus price target hints at a 328.6% upside potential for Bionomics Limited Unsponsored ADR (BNOX). While empirical research shows that this sought-after metric is hardly effective, an upward tr...

4 weeks ago - Zacks Investment Research

Bionomics reports Full Year Financial Results

ADELAIDE, Australia, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX:BNO, Nasdaq:BNOX), today announced its financial results for the 12 months ended 30 June 2022.

1 month ago - GlobeNewsWire

Bionomics Receives R&D Tax Incentive Refund for FY2021 of A$2.1M

ADELAIDE, Australia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, NASDAQ:BNOX), a clinical stage biopharmaceutical company, is pleased to announce that the Company has received A$2,085...

1 month ago - GlobeNewsWire

Quarterly Activities Report for June 2022

ADELAIDE, Australia, July 29, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a global, clinical stage biopharmaceutical company, today released its Quarterl...

1 month ago - GlobeNewsWire

Bionomics to Participate in William Blair's Biotech Focus Conference 2022

ADELAIDE, Australia, July 08, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion cha...

2 months ago - GlobeNewsWire

Bionomics Limited to Participate in the H.C. Wainwright Mental Health Conference

ADELAIDE, Australia, June 27, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion cha...

3 months ago - GlobeNewsWire

Bionomics Investor Webinar

ADELAIDE, Australia, June 13, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO |Nasdaq: BNOX ), (Bionomics or the Company), a clinical-stage biopharmaceutical company developing novel, allosteric io...

3 months ago - GlobeNewsWire

Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted on Tuesday

We've seen a large array of halted stocks today as circuit breakers take effect to reign in unexpected volatility for some shares. The post Halted Stocks: 9 Circuit Breaker Stocks That Have Been Halted ...

3 months ago - InvestorPlace

Bionomics Limited to Participate in Upcoming Investor Conferences

ADELAIDE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX | ASX: BNO) (Bionomics or Company), a clinical-stage biopharmaceutical company developing novel, allosteric ion chan...

4 months ago - GlobeNewsWire

6 Stocks Halted In Wednesday's Session

A circuit breaker is an automatic, temporary trading halt on certain securities when the underlying stock is experiencing times of high volatility. It is a measure put in place to help restore and bring...

Other symbols: AKBADOGLOBREVBSKYH
5 months ago - Benzinga

Bionomics' Half-Year Report

ADELAIDE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Bionomics Limited (ASX: BNO, Nasdaq: BNOX), today announced its half-year report for the half-year ended 31 December 2021. The half-year ending 31 ...

7 months ago - GlobeNewsWire

Bionomics Limited participated in the H.C Wainwright BioConnect Conference

ADELAIDE, Australia, Jan. 12, 2022 /PRNewswire/ -- Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, participated in the H.C Wainwright BioConn...

8 months ago - PRNewsWire

Bionomics Initiates Phase 2 PREVAIL Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

EASTWOOD, Australia, Jan. 3, 2022 /PRNewswire/ -- Bionomics Limited (ASX: BNO, NASDAQ: BNOX) (Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that it has initia...

8 months ago - PRNewsWire